Lupin is prepping a $1B US deal spree; Protagonist raising $60M for trial work
→ Coming off of a $150 million deal to buy Symbiomix, Mumbai-based Lupin says it’s planning a $1 billion deal spree aimed at building a women’s health group in the US.
→ Protagonist Therapeutics $PTGX is raising $60 million through a private offering. The money will be earmarked for its clinical work on three drug candidates: PTG-100, PTG-200, and PTG-300.
→ AstraZeneca spinoff Entasis has bagged its second CARB-X award for its work on new antibiotics. The Waltham, MA-based biotech gets $3.8 million initially plus a shot at another $6.3 million.
→ Holliston, MA-based Biostage is blaming a failed financing deal for its financial woes, forcing the company to lay off 17 staffers — 71% of its workforce. The company works on bioengineered organ transplants.
→ The FDA is giving Eli Lilly’s abemaciclib a priority review for advanced breast cancer. The agency came through with the accelerated review after it looked over the MONARCH 3 data.